Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,787,343
  • Shares Outstanding, K 140,404
  • Annual Sales, $ 983,710 K
  • Annual Income, $ -545,060 K
  • 60-Month Beta 1.99
  • Price/Sales 1.81
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 75.95% ( -7.96%)
  • Historical Volatility 104.42%
  • IV Percentile 3%
  • IV Rank 35.34%
  • IV High 187.27% on 05/13/24
  • IV Low 15.11% on 11/28/23
  • Put/Call Vol Ratio 0.23
  • Today's Volume 11,060
  • Volume Avg (30-Day) 36,671
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 377,442
  • Open Int (30-Day) 386,749

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 1.13
  • Number of Estimates 5
  • High Estimate 2.67
  • Low Estimate -0.81
  • Prior Year 0.58
  • Growth Rate Est. (year over year) +94.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.35 +5.02%
on 06/28/24
23.86 -45.64%
on 06/06/24
-2.06 (-13.71%)
since 05/31/24
3-Month
3.81 +240.42%
on 04/18/24
23.86 -45.64%
on 06/06/24
+8.44 (+186.31%)
since 04/02/24
52-Week
3.53 +267.17%
on 02/05/24
23.86 -45.64%
on 06/06/24
+5.54 (+74.56%)
since 06/30/23

Most Recent Stories

More News
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

/CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, announced that it has filed for...

NVAX : 12.97 (+1.89%)
Where Will Novavax Be in 1 Year?

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

NVAX : 12.97 (+1.89%)
SNY : 48.54 (-2.12%)
Is It Too Late to Buy Novavax Stock?

Shares of the vaccine maker are trading up 230% this year.

NVAX : 12.97 (+1.89%)
SNY : 48.54 (-2.12%)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar

These pharma and biotech players could become long-term winners.

SNY : 48.54 (-2.12%)
NVAX : 12.97 (+1.89%)
PFE : 27.83 (-1.38%)
DNA : 0.3465 (+7.21%)
Why Vaccine Stocks Rallied This Week

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

SNY : 48.54 (-2.12%)
MRNA : 117.07 (+0.97%)
NVAX : 12.97 (+1.89%)
BNTX : 78.76 (-0.09%)
PFE : 27.83 (-1.38%)
Better Buy: Inovio Pharmaceuticals vs. Novavax

Both biotechs have been struggling for a while, but there might be some hope for them.

PFE : 27.83 (-1.38%)
NVAX : 12.97 (+1.89%)
INO : 8.43 (-2.09%)
3 Things You Need to Know If You Buy Novavax Today

The vaccine maker's recovery story is looking brighter.

SNY : 48.54 (-2.12%)
PFE : 27.83 (-1.38%)
NVAX : 12.97 (+1.89%)
This Stock Just More Than Doubled in 1 Day: Is It a Buy?

The biotech still hasn't lost momentum.

NVAX : 12.97 (+1.89%)
SNY : 48.54 (-2.12%)
Is Novavax Stock a Buy?

Can Novavax's stock continue soaring?

NVAX : 12.97 (+1.89%)
Could Novavax Become the Next Moderna?

Sanofi believes in Novavax's vaccine strengths...

SNY : 48.54 (-2.12%)
PFE : 27.83 (-1.38%)
NVAX : 12.97 (+1.89%)
MRNA : 117.07 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 13.78
2nd Resistance Point 13.45
1st Resistance Point 13.21
Last Price 12.97
1st Support Level 12.64
2nd Support Level 12.31
3rd Support Level 12.07

See More

52-Week High 23.86
Fibonacci 61.8% 16.09
Fibonacci 50% 13.70
Last Price 12.97
Fibonacci 38.2% 11.30
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar